索托拉西布对合并间质性肺炎的阳性肺腺癌患者的耐受性：一例报告。
Tolerability of sotorasib for positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report.
作者信息
Okada Kohei, Sakakibara Rie, Honda Takayuki, Mitsumura Takahiro, Shibata Sho, Shirai Tsuyoshi, Okamoto Tsukasa, Furusawa Haruhiko, Tateishi Tomoya, Miyazaki Yasunari
机构信息
Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pulmonary Immunotherapeutic, Tokyo Medical and Dental University, Tokyo, Japan.
出版信息
Respir Med Case Rep. 2023 Oct 14;46:101929. doi: 10.1016/j.rmcr.2023.101929. eCollection 2023.
A 74-year-old man was referred to our hospital with an abnormal chest shadow. Computed tomography (CT) revealed a mass in the left upper lobe and interstitial pneumonia (IP). The patient underwent CT-guided needle biopsy and was diagnosed as lung adenocarcinoma with cT2aN1M1a Stage IVA (PUL). The patient was administered 6 cycles of CBDCA + nab-paclitaxel as first-line, 3 cycles of atezolizumab as second-line, and 8 cycles of S-1 as third-line treatment but finally showed tumor progression. Because comprehensive genome profiling test revealed G12C mutation, sotorasib was initiated as fourth-line treatment and showed tumor regression without exacerbation of pre-existing IP.
一名74岁男性因胸部阴影异常被转诊至我院。计算机断层扫描（CT）显示左上叶有一个肿块以及间质性肺炎（IP）。患者接受了CT引导下的针吸活检，被诊断为cT2aN1M1a IVA期（肺）肺腺癌。患者一线接受了6个周期的顺铂+白蛋白结合型紫杉醇治疗，二线接受了3个周期的阿替利珠单抗治疗，三线接受了8个周期的替吉奥治疗，但最终出现肿瘤进展。由于综合基因组分析测试显示存在G12C突变，因此开始使用索托拉西布作为四线治疗，结果显示肿瘤消退且原有间质性肺炎未加重。
Zotero 插件